8-K: Cytek Biosciences Q2 2025 Revenue Dips 2%

Cytek Biosciences reported a 2% decrease in Q2 2025 total revenue to $45.6 million, alongside a new product launch and increased recurring revenue.

Summary

• Total revenue for the second quarter of 2025 was $45.6 million, a 2% decrease compared to the second quarter of 2024.
• The total installed base of Cytek instruments expanded to 3,295, with 146 units added in Q2 2025, representing 3% unit growth of Cytek FSP instruments compared to Q2 2024.
• The Cytek Aurora Evo system, an improved full spectrum flow cytometer, was launched, offering faster sample throughput, automated startup/shutdown, enhanced small particle detection, and data harmonization.
• Total recurring revenue, comprising service and reagent revenues, grew 16% compared to Q2 2024 and accounts for 32% of the last 12 months' total revenue.
• Cytek repurchased $4.5 million of its common stock in open market purchases during Q2 2025.
• GAAP gross profit was $23.9 million for Q2 2025, a 6% decrease compared to Q2 2024, with a GAAP gross profit margin of 52% (down from 55%).
• Adjusted gross profit margin was 56% in Q2 2025, compared to 58% in Q2 2024.
• Operating expenses increased by 2% to $34.5 million in Q2 2025.
• Research and development expenses decreased by 12% to $8.8 million in Q2 2025.
• Sales and marketing expenses decreased by 1% to $12.1 million in Q2 2025.
• General and administrative expenses increased by 16% to $13.5 million in Q2 2025.
• Loss from operations was $10.6 million in Q2 2025, compared to a loss of $8.5 million in Q2 2024.
• Net loss was $5.6 million in Q2 2025, compared to a net loss of $10.4 million in Q2 2024.
• Adjusted EBITDA was $1.3 million in Q2 2025, compared to $2.9 million in Q2 2024.
• Adjusted EBITDA excluding investment income was a loss of $0.8 million in Q2 2025, compared to positive $1.0 million in Q2 2024.
• Cash and marketable securities were $262.0 million as of June 30, 2025, a decrease of $3.6 million from March 31, 2025, despite the $4.5 million stock repurchase.
• Full year 2025 revenue guidance was narrowed to a range of $196 million to $205 million, representing growth of -2% to +2% over full year 2024.

Sentiment

Score: 4

Explanation: While the company launched a new product and saw growth in recurring revenue, overall revenue declined, and profitability metrics (gross profit, operating loss, Adjusted EBITDA) worsened year-over-year. The full-year guidance also indicates potential for negative growth, reflecting a challenging market.

Positives

• Recurring revenue, comprised of service and reagent revenues, grew 16% year-over-year and now accounts for 32% of the last 12 months' total revenue.
• Successfully launched the Cytek Aurora Evo system, an enhanced full spectrum flow cytometer with improved features.
• Net loss significantly reduced to $5.6 million in Q2 2025 from $10.4 million in Q2 2024.
• Expanded the total installed base of Cytek instruments by 146 units in Q2 2025, reaching 3,295 units.
• Repurchased $4.5 million of common stock in Q2 2025, indicating confidence in the company's value.
• Service revenue grew worldwide, and product revenue increased in the U.S.
• Maintained a strong cash and marketable securities position of $262.0 million as of June 30, 2025.

Negatives

• Total revenue decreased by 2% year-over-year to $45.6 million.
• GAAP gross profit decreased by 6% to $23.9 million.
• GAAP gross profit margin declined to 52% from 55% year-over-year.
• Adjusted gross profit margin declined to 56% from 58% year-over-year.
• Loss from operations increased to $10.6 million from $8.5 million year-over-year.
• Adjusted EBITDA decreased to $1.3 million from $2.9 million year-over-year.
• Adjusted EBITDA excluding investment income turned negative at $(0.8) million from positive $1.0 million year-over-year.
• Product revenue decreased in EMEA and APAC regions.
• General and administrative expenses increased by 16% year-over-year.
• Full year 2025 revenue guidance was narrowed to a range that includes potential negative growth (-2% to +2%).

Risks

• Global geopolitical, economic, and market conditions.
• Ability to manage the impacts of recent and future export controls and licensing requirements, tariffs, and NIH funding policies on the business.
• Ability to accurately forecast customer demand and adoption of products.
• Dependence on certain sole and single-source suppliers.
• Competition in the cell analysis solutions market.
• Market acceptance of current and potential products.
• Ability to manage the growth and complexity of the organization, maintain relationships with customers and suppliers, and hire and retain key employees.
• Ability to manufacture products in high-quality commercial quantities successfully and consistently to meet demand.
• Ability to increase penetration in existing markets and expand into adjacent markets.
• Ability to secure additional distributors or maintain good relationships with existing distributors.
• Ability to successfully develop and introduce new products.
• Ability to maintain, protect, and enhance intellectual property.
• Ability to continue to stay in compliance with material contractual obligations, applicable laws, and regulations.
• Foreign currency exchange impacts.

Future Outlook

Management expects the instrument market to recover over time and is focused on expanding the global installed base to support parallel growth in recurring revenue through service and reagent businesses. The company plans to continue strengthening market leadership through innovation that redefines industry standards and creates new markets. Full year 2025 revenue guidance has been narrowed to a range of $196 million to $205 million, representing -2% to +2% growth over full year 2024, assuming no change from current currency exchange rates.

Management Comments

• "The progress we achieved in the first half of this year is underscored by steady growth in our FSP unit placements, and in our recurring revenue businesses, despite a macro environment that remains challenging."
• "I am also proud of our teams continued focus on innovation and the launch of the Cytek Aurora Evo system, which we believe will accelerate broader adoption of our solutions."
• "Looking ahead, we remain focused on expanding our installed base globally, which supports our parallel goal of growing our recurring revenue through our service and reagent businesses."
• "Further, we plan to continue strengthening our market leadership through innovation that redefines industry standards and creates new markets."
• "We expect the instrument market to recover over time and are poised to emerge in an even stronger position than we are today with a focus on these longer-term growth drivers for our business."

Industry Context

Cytek Biosciences operates in the cell analysis solutions market, specifically in flow cytometry. The launch of the Aurora Evo system demonstrates continued innovation in a competitive sector. The company's acknowledgment of a 'challenging macro environment' affecting instrument sales aligns with broader industry trends where capital equipment purchases can be sensitive to economic uncertainty. The strategic emphasis on growing recurring revenue from services and reagents is a common industry approach to build more stable and predictable revenue streams, reducing reliance on cyclical instrument sales.

Comparison to Industry Standards

• The filing does not provide specific comparable company or project results to benchmark against industry standards. However, the company states it uses non-GAAP measures to benchmark its performance externally against competitors.

Legal Proceedings

• The balance sheet lists a legal settlement liability, but the filing does not detail any new legal proceedings or regulatory matters.

Stakeholder Impact

• Shareholders: Mixed results with revenue decline and profitability challenges, but also a stock repurchase and focus on long-term growth drivers. Potential for continued share price volatility.
• Employees: Continued focus on innovation and market leadership suggests stability, but the challenging macro environment could imply operational pressures.
• Customers: The launch of the new Cytek Aurora Evo system offers improved features, potentially enhancing customer experience and adoption. The expanded installed base indicates continued customer acquisition.
• Suppliers: Dependence on certain sole and single-source suppliers is identified as a risk factor, implying potential supply chain vulnerabilities.
• Creditors: A strong cash and marketable securities position of $262.0 million suggests good liquidity.

Next Steps

• Expand the installed base globally.
• Grow recurring revenue through service and reagent businesses.
• Strengthen market leadership through innovation that redefines industry standards and creates new markets.
• Host a conference call on August 6, 2025, to discuss Q2 2025 financial results.
• File the Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025, on or about August 6, 2025.

Key Dates

Recommendation

The company reported a decline in total revenue, gross profit, and Adjusted EBITDA, alongside an increased operating loss for Q2 2025. While there are positive developments such as 16% growth in recurring revenue, the launch of the Cytek Aurora Evo system, and a $4.5 million stock repurchase, the overall financial performance indicates a challenging macro environment and operational headwinds. The narrowed 2025 revenue guidance, which includes potential negative growth, suggests continued near-term pressure. Investors should hold to monitor if the strategic initiatives, particularly the growth in recurring revenue and new product adoption, can offset the declining instrument sales and improve overall profitability in future quarters.

Keywords

Cell Analysis, Flow Cytometry, Biotechnology, Life Sciences, Research Instruments, Cytek Aurora, Full Spectrum Profiling, Financial Results, Quarterly Report